Drug intelligence / Profile preview

Calminox AD

Development stage
Unknown
Lead developer
Percos
Modality
Small Molecules
Administration
Topical
01

Overview

Calminox AD is a topical anti-dandruff shampoo developed and marketed by Percos. It is formulated as a fixed-dose combination containing the antifungal agent ketoconazole (2% w/v) and Ichthyol Pale (sodium shale oil sulfonate, 0.5%). Ketoconazole acts by inhibiting fungal lanosterol 14-alpha demethylase, thereby disrupting ergosterol synthesis and cell membrane integrity in *Malassezia* yeasts, the primary causative organisms of dandruff and seborrheic dermatitis. Ichthyol Pale provides complementary anti-inflammatory, anti-itch, and antiseborrheic properties, helping to soothe scalp irritation, reduce redness, and regulate sebum production. Calminox AD is indicated for the treatment and prevention of dandruff, seborrheic dermatitis, and associated scalp flaking and pruritus.

Brand names
Calminox ADCalminox AD ShampooCalminox Anti Dandruff Shampoo
Other names
ketoconazole + ichthyol paleketoconazole + sodium shale oil sulfonate
02

Targets

CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on Calminox AD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calminox AD.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call